MoonLake (MLTX) news
Recent news
Moonlake Immunotherapeutics - Submits BLA to FDA for Sone Lokimab to treat hidradenitis suppurativa - SEC filing
MoonLake Immunotherapeutics AG (NASDAQ: MLTX) has confirmed its clinical evidence strategy for the submission of a Biologic License Application (BLA) for sonelokimab (SLK) in the treatment of hidradenitis suppurativa (HS), with a planned submission in H2 2026 . This follows recent interactions with…
AInvest Wire · Sep 30, 2026H.C. Wainwright raises target price to $50 from $45 for MoonLake Immunotherapeutics
AInvest Wire · Aug 13, 2026Moonlake sinks 26% after topline results update
Moonlake Therapeutics (MLTX) shares declined 26% following the release of topline results from a key clinical trial, disappointing investors despite ongoing progress in its drug development pipeline. The company reported that the trial did not meet its primary endpoints, raising concerns about the…
AInvest Wire · Aug 10, 2026Moonlake prices offering of 9M shares at $20 each
MoonLake Immunotherapeutics AG (Nasdaq: MLTX) has priced an underwritten offering of 9 million Class A ordinary shares at $20 per share, according to a recent announcement. The offering is expected to generate gross proceeds of approximately $180 million before deducting underwriting discounts and…
AInvest Wire · Jun 24, 2026Moonlake Immunotherapeutics pricing of upsized $200M offering
MoonLake Immunotherapeutics (NASDAQ: MLTX) has priced an upsized public offering of Class A Ordinary Shares, raising gross proceeds of approximately $460 million in June 2023. This financing marked a significant milestone for the company, providing substantial capital to advance the development of…
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.